BGF World Healthscience I4 USD
LU2297183803
BGF World Healthscience I4 USD/ LU2297183803 /
NAV11/10/2024 |
Diferencia+0.0500 |
Tipo de beneficio |
Enfoque de la inversión |
Sociedad de fondos |
12.9200USD |
+0.39% |
paying dividend |
Equity
Worldwide
|
BlackRock (LU) ▶ |
Estrategia de inversión
The Fund aims to maximise the return on your investment through a combination of capital growth and income on the Fund"s assets and invest in a manner consistent with the principles of environmental, social and governance (ESG) investing. The Fund invests globally at least 70% of its total assets in the equity securities (e.g. shares) of companies the main business of which is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology.
The investment adviser (IA) may use financial derivative instruments (FDIs) (i.e. investments the prices of which are based on one or more underlying assets) for investment purposes in order to achieve the investment objective of the Fund, and/or to reduce risk within the Fund"s portfolio, reduce investment costs and generate additional income. The Fund may, via FDIs, generate varying amounts of market leverage (i.e. where the Fund gains market exposure in excess of the value of its assets). The Fund is actively managed, and the IA has discretion to select the Fund's investments. In doing, the IA will refer to the MSCI World Health Care Index (the "Index") when constructing the Fund"s portfolio, and also for performance comparison and risk management purposes, as further described in the prospectus. The IA is not bound by the components or weighting of the Index. and may also use its discretion to invest in securities not included in the Index. However, the sector requirements of the investment objective and policy may limit the extent to which the portfolio holdings will deviate from the Index.
Objetivo de inversión
The Fund aims to maximise the return on your investment through a combination of capital growth and income on the Fund"s assets and invest in a manner consistent with the principles of environmental, social and governance (ESG) investing. The Fund invests globally at least 70% of its total assets in the equity securities (e.g. shares) of companies the main business of which is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology.
Datos maestros
Tipo de beneficio: |
paying dividend |
Categoría de fondos: |
Equity |
Región: |
Worldwide |
Sucursal: |
Sector Health / Pharma |
Punto de referencia: |
MSCI World Health Care Index |
Inicio del año fiscal: |
01/09 |
Última distribución: |
30/08/2024 |
Banco depositario: |
The Bank of New York Mellon SA/NV, Zweigniederlassung Luxemburg |
País de origen: |
Luxembourg |
Permiso de distribución: |
Austria, Germany, Switzerland, Luxembourg, Czech Republic |
Gestor de fondo: |
Erin Xie, Xiang Liu |
Volumen de fondo: |
14.72 mil millones
USD
|
Fecha de fundación: |
03/03/2021 |
Enfoque de la inversión: |
- |
Condiciones
Recargo de emisión: |
0.00% |
Max. Comisión de administración: |
0.75% |
Inversión mínima: |
10,000,000.00 USD |
Deposit fees: |
0.45% |
Cargo por amortización: |
0.00% |
Prospecto simplificado: |
Descargar (Versión para imprimir) |
Sociedad de fondos
Fondos de empresa: |
BlackRock (LU) |
Dirección: |
35a Avenue JF Kennedy, 1855, Luxemburg |
País: |
Luxembourg |
Internet: |
www.blackrock.com
|
Activos
Stocks |
|
96.93% |
Mutual Funds |
|
2.74% |
Cash |
|
0.33% |
Países
United States of America |
|
69.95% |
Denmark |
|
6.24% |
Switzerland |
|
6.03% |
United Kingdom |
|
4.48% |
France |
|
3.95% |
Ireland |
|
1.45% |
Germany |
|
1.19% |
Netherlands |
|
1.19% |
Australia |
|
1.03% |
Japan |
|
0.90% |
Belgium |
|
0.45% |
Cash |
|
0.33% |
Otros |
|
2.81% |
Sucursales
Pharma/Biotechnology |
|
50.78% |
Healthcare services |
|
21.59% |
Healthcare appliances |
|
19.84% |
Parma, wholesale |
|
4.68% |
Cash |
|
0.33% |
Otros |
|
2.78% |